Lipopolysaccharide‐induced hypothalamic inflammation in cancer cachexia‐anorexia is amplified by tumour‐derived prostaglandin E2

Abstract Background Cachexia‐anorexia syndrome is a complex metabolic condition characterized by skeletal muscle wasting, reduced food intake and prominent involvement of systemic and central inflammation. Here, the gut barrier function was investigated in pancreatic cancer‐induced cachexia mouse mo...

Full description

Bibliographic Details
Main Authors: Xiaolin Li, Tosca Holtrop, Fleur A.C. Jansen, Brennan Olson, Pete Levasseur, Xinxia Zhu, Mieke Poland, Winni Schalwijk, Renger F. Witkamp, Daniel L. Marks, Klaske vanNorren
Format: Article
Language:English
Published: Wiley 2022-12-01
Series:Journal of Cachexia, Sarcopenia and Muscle
Subjects:
Online Access:https://doi.org/10.1002/jcsm.13093
_version_ 1827280021822111744
author Xiaolin Li
Tosca Holtrop
Fleur A.C. Jansen
Brennan Olson
Pete Levasseur
Xinxia Zhu
Mieke Poland
Winni Schalwijk
Renger F. Witkamp
Daniel L. Marks
Klaske vanNorren
author_facet Xiaolin Li
Tosca Holtrop
Fleur A.C. Jansen
Brennan Olson
Pete Levasseur
Xinxia Zhu
Mieke Poland
Winni Schalwijk
Renger F. Witkamp
Daniel L. Marks
Klaske vanNorren
author_sort Xiaolin Li
collection DOAJ
description Abstract Background Cachexia‐anorexia syndrome is a complex metabolic condition characterized by skeletal muscle wasting, reduced food intake and prominent involvement of systemic and central inflammation. Here, the gut barrier function was investigated in pancreatic cancer‐induced cachexia mouse models by relating intestinal permeability to the degree of cachexia. We further investigated the involvement of the gut–brain axis and the crosstalk between tumour, gut and hypothalamus in vitro. Methods Two distinct mouse models of pancreatic cancer cachexia (KPC and 4662) were used. Intestinal inflammation and permeability were assessed through fluorescein isothiocyanate dextran (FITC‐dextran) and lipopolysaccharide (LPS), and hypothalamic and systemic inflammation through mRNA expression and plasma cytokines, respectively. To simulate the tumour–gut–brain crosstalk, hypothalamic (HypoE‐N46) cells were incubated with cachexia‐inducing tumour secretomes and LPS. A synthetic mimic of C26 secretome was produced based on its secreted inflammatory mediators. Each component of the mimic was systematically omitted to narrow down the key mediator(s) with an amplifying inflammation. To substantiate its contribution, cyclooxygenase‐2 (COX‐2) inhibitor was used. Results In vivo experiments showed FITC‐dextran was enhanced in the KPC group (362.3 vs. sham 111.4 ng/mL, P < 0.001). LPS was increased to 140.9 ng/mL in the KPC group, compared with sham and 4662 groups (115.8 and 115.8 ng/mL, P < 0.05). Hypothalamic inflammatory gene expression of Ccl2 was up‐regulated in the KPC group (6.3 vs. sham 1, P < 0.0001, 4662 1.3, P < 0.001), which significantly correlated with LPS concentration (r = 0.4948, P = 0.0226). These data suggest that intestinal permeability is positively related to the cachexic degree. Prostaglandin E2 (PGE2) was confirmed to be present in the plasma and PGE2 concentration (log10) in the KPC group was much higher than in 4662 group (1.85 and 0.56 ng/mL, P < 0.001), indicating a role for PGE2 in pancreatic cancer‐induced cachexia. Parallel to in vivo findings, in vitro experiments revealed that the cachexia‐inducing tumour secretomes (C26, LLC, KPC and 4662) amplified LPS‐induced hypothalamic IL‐6 secretion (419%, 321%, 294%, 160%). COX‐2 inhibitor to the tumour cells reduced PGE2 content (from 105 to 102 pg/mL) in the secretomes and eliminated the amplified hypothalamic IL‐6 production. Moreover, results could be reproduced by addition of PGE2 alone, indicating that the increased hypothalamic inflammation is directly related to the PGE2 from tumour. Conclusions PGE2 secreted by the tumour may play a role in amplifying the effects of bacteria‐derived LPS on the inflammatory hypothalamic response. The cachexia‐inducing potential of tumour mice models parallels the loss of intestinal barrier function. Tumour‐derived PGE2 might play a key role in cancer‐related cachexia‐anorexia syndrome via tumour–gut–brain crosstalk.
first_indexed 2024-04-11T13:58:59Z
format Article
id doaj.art-29f9d48912b94de994b5625095893167
institution Directory Open Access Journal
issn 2190-5991
2190-6009
language English
last_indexed 2024-04-24T08:29:49Z
publishDate 2022-12-01
publisher Wiley
record_format Article
series Journal of Cachexia, Sarcopenia and Muscle
spelling doaj.art-29f9d48912b94de994b56250958931672024-04-16T20:10:20ZengWileyJournal of Cachexia, Sarcopenia and Muscle2190-59912190-60092022-12-011363014302710.1002/jcsm.13093Lipopolysaccharide‐induced hypothalamic inflammation in cancer cachexia‐anorexia is amplified by tumour‐derived prostaglandin E2Xiaolin Li0Tosca Holtrop1Fleur A.C. Jansen2Brennan Olson3Pete Levasseur4Xinxia Zhu5Mieke Poland6Winni Schalwijk7Renger F. Witkamp8Daniel L. Marks9Klaske vanNorren10Nutritional Biology, Division of Human Nutrition Wageningen University Wageningen The NetherlandsNutritional Biology, Division of Human Nutrition Wageningen University Wageningen The NetherlandsNutritional Biology, Division of Human Nutrition Wageningen University Wageningen The NetherlandsPapé Family Pediatric Research Institute Oregon Health & Science University (OHSU) Portland OR USAPapé Family Pediatric Research Institute Oregon Health & Science University (OHSU) Portland OR USAPapé Family Pediatric Research Institute Oregon Health & Science University (OHSU) Portland OR USANutritional Biology, Division of Human Nutrition Wageningen University Wageningen The NetherlandsNutritional Biology, Division of Human Nutrition Wageningen University Wageningen The NetherlandsNutritional Biology, Division of Human Nutrition Wageningen University Wageningen The NetherlandsPapé Family Pediatric Research Institute Oregon Health & Science University (OHSU) Portland OR USANutritional Biology, Division of Human Nutrition Wageningen University Wageningen The NetherlandsAbstract Background Cachexia‐anorexia syndrome is a complex metabolic condition characterized by skeletal muscle wasting, reduced food intake and prominent involvement of systemic and central inflammation. Here, the gut barrier function was investigated in pancreatic cancer‐induced cachexia mouse models by relating intestinal permeability to the degree of cachexia. We further investigated the involvement of the gut–brain axis and the crosstalk between tumour, gut and hypothalamus in vitro. Methods Two distinct mouse models of pancreatic cancer cachexia (KPC and 4662) were used. Intestinal inflammation and permeability were assessed through fluorescein isothiocyanate dextran (FITC‐dextran) and lipopolysaccharide (LPS), and hypothalamic and systemic inflammation through mRNA expression and plasma cytokines, respectively. To simulate the tumour–gut–brain crosstalk, hypothalamic (HypoE‐N46) cells were incubated with cachexia‐inducing tumour secretomes and LPS. A synthetic mimic of C26 secretome was produced based on its secreted inflammatory mediators. Each component of the mimic was systematically omitted to narrow down the key mediator(s) with an amplifying inflammation. To substantiate its contribution, cyclooxygenase‐2 (COX‐2) inhibitor was used. Results In vivo experiments showed FITC‐dextran was enhanced in the KPC group (362.3 vs. sham 111.4 ng/mL, P < 0.001). LPS was increased to 140.9 ng/mL in the KPC group, compared with sham and 4662 groups (115.8 and 115.8 ng/mL, P < 0.05). Hypothalamic inflammatory gene expression of Ccl2 was up‐regulated in the KPC group (6.3 vs. sham 1, P < 0.0001, 4662 1.3, P < 0.001), which significantly correlated with LPS concentration (r = 0.4948, P = 0.0226). These data suggest that intestinal permeability is positively related to the cachexic degree. Prostaglandin E2 (PGE2) was confirmed to be present in the plasma and PGE2 concentration (log10) in the KPC group was much higher than in 4662 group (1.85 and 0.56 ng/mL, P < 0.001), indicating a role for PGE2 in pancreatic cancer‐induced cachexia. Parallel to in vivo findings, in vitro experiments revealed that the cachexia‐inducing tumour secretomes (C26, LLC, KPC and 4662) amplified LPS‐induced hypothalamic IL‐6 secretion (419%, 321%, 294%, 160%). COX‐2 inhibitor to the tumour cells reduced PGE2 content (from 105 to 102 pg/mL) in the secretomes and eliminated the amplified hypothalamic IL‐6 production. Moreover, results could be reproduced by addition of PGE2 alone, indicating that the increased hypothalamic inflammation is directly related to the PGE2 from tumour. Conclusions PGE2 secreted by the tumour may play a role in amplifying the effects of bacteria‐derived LPS on the inflammatory hypothalamic response. The cachexia‐inducing potential of tumour mice models parallels the loss of intestinal barrier function. Tumour‐derived PGE2 might play a key role in cancer‐related cachexia‐anorexia syndrome via tumour–gut–brain crosstalk.https://doi.org/10.1002/jcsm.13093Hypothalamic inflammationProstaglandinGut–brain axisCancerCachexia
spellingShingle Xiaolin Li
Tosca Holtrop
Fleur A.C. Jansen
Brennan Olson
Pete Levasseur
Xinxia Zhu
Mieke Poland
Winni Schalwijk
Renger F. Witkamp
Daniel L. Marks
Klaske vanNorren
Lipopolysaccharide‐induced hypothalamic inflammation in cancer cachexia‐anorexia is amplified by tumour‐derived prostaglandin E2
Journal of Cachexia, Sarcopenia and Muscle
Hypothalamic inflammation
Prostaglandin
Gut–brain axis
Cancer
Cachexia
title Lipopolysaccharide‐induced hypothalamic inflammation in cancer cachexia‐anorexia is amplified by tumour‐derived prostaglandin E2
title_full Lipopolysaccharide‐induced hypothalamic inflammation in cancer cachexia‐anorexia is amplified by tumour‐derived prostaglandin E2
title_fullStr Lipopolysaccharide‐induced hypothalamic inflammation in cancer cachexia‐anorexia is amplified by tumour‐derived prostaglandin E2
title_full_unstemmed Lipopolysaccharide‐induced hypothalamic inflammation in cancer cachexia‐anorexia is amplified by tumour‐derived prostaglandin E2
title_short Lipopolysaccharide‐induced hypothalamic inflammation in cancer cachexia‐anorexia is amplified by tumour‐derived prostaglandin E2
title_sort lipopolysaccharide induced hypothalamic inflammation in cancer cachexia anorexia is amplified by tumour derived prostaglandin e2
topic Hypothalamic inflammation
Prostaglandin
Gut–brain axis
Cancer
Cachexia
url https://doi.org/10.1002/jcsm.13093
work_keys_str_mv AT xiaolinli lipopolysaccharideinducedhypothalamicinflammationincancercachexiaanorexiaisamplifiedbytumourderivedprostaglandine2
AT toscaholtrop lipopolysaccharideinducedhypothalamicinflammationincancercachexiaanorexiaisamplifiedbytumourderivedprostaglandine2
AT fleuracjansen lipopolysaccharideinducedhypothalamicinflammationincancercachexiaanorexiaisamplifiedbytumourderivedprostaglandine2
AT brennanolson lipopolysaccharideinducedhypothalamicinflammationincancercachexiaanorexiaisamplifiedbytumourderivedprostaglandine2
AT petelevasseur lipopolysaccharideinducedhypothalamicinflammationincancercachexiaanorexiaisamplifiedbytumourderivedprostaglandine2
AT xinxiazhu lipopolysaccharideinducedhypothalamicinflammationincancercachexiaanorexiaisamplifiedbytumourderivedprostaglandine2
AT miekepoland lipopolysaccharideinducedhypothalamicinflammationincancercachexiaanorexiaisamplifiedbytumourderivedprostaglandine2
AT winnischalwijk lipopolysaccharideinducedhypothalamicinflammationincancercachexiaanorexiaisamplifiedbytumourderivedprostaglandine2
AT rengerfwitkamp lipopolysaccharideinducedhypothalamicinflammationincancercachexiaanorexiaisamplifiedbytumourderivedprostaglandine2
AT daniellmarks lipopolysaccharideinducedhypothalamicinflammationincancercachexiaanorexiaisamplifiedbytumourderivedprostaglandine2
AT klaskevannorren lipopolysaccharideinducedhypothalamicinflammationincancercachexiaanorexiaisamplifiedbytumourderivedprostaglandine2